enGene Therapeutics (ENGN) Capital Expenditures (2023 - 2026)
enGene Therapeutics' Capital Expenditures was $98,000 in fiscal Q2 2026 (quarter ended Apr 30, 2026), up 117.8% from $45,000 a year earlier but down 35.9% from the prior quarter.
Powered by 
Analysis
enGene Therapeutics (ENGN) Capital Expenditures (2023 - 2026) Analysis & Trends
For FY2025 (ended Oct 31, 2025), Capital Expenditures at enGene Therapeutics came in at $1.49 million, up 60.5% from FY2024.
- Capital Expenditures has now increased for three consecutive fiscal years, with a three-year compound annual growth rate of 113.3% (FY2022 to FY2025).
- In earlier fiscal years, Capital Expenditures was $925,000 in FY2024 (+190.9%), $318,000 in FY2023 (+107.8%) and $153,000 in FY2022.
- Quarterly Capital Expenditures has moved between $2,000 (fiscal Q3 2024) and $704,000 (fiscal Q3 2025) over five years.
- Compared with a year earlier, Capital Expenditures was higher in three of the last seven quarters, with growth averaging 1.5%.
- Per Business Quant data, ENGN's Capital Expenditures in the three fiscal quarters before Q2 2026 was $153,000 (Q1 2026), $437,000 (Q4 2025) and $704,000 (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,230.11 Bn | 1,198.70 Bn | 19.71 Bn | 2.93 Bn |
| 2 | Johnson & Johnson | 644.39 Bn | 564.25 Bn | 17.30 Bn | 1.36 Bn |
| 3 | AbbVie | 503.52 Bn | 476.68 Bn | 12.70 Bn | 322.00 Mn |
| 4 | Merck | 363.29 Bn | 317.72 Bn | 12.21 Bn | 893.00 Mn |
| 5 | Novartis Ag | 298.23 Bn | 262.62 Bn | 11.24 Bn | 321.00 Mn |
| 6 | Astrazeneca | 267.53 Bn | 241.29 Bn | 12.86 Bn | 1.86 Bn |
| 7 | Amgen | 241.80 Bn | 197.20 Bn | 7.24 Bn | 513.00 Mn |
| 8 | Gilead Sciences | 195.07 Bn | 169.19 Bn | 6.22 Bn | 140.00 Mn |
| 9 | Pfizer | 173.33 Bn | 120.28 Bn | 10.94 Bn | 533.00 Mn |
| 10 | enGene Therapeutics | 105.88 Mn | -888.59 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | 98,000.00 |
| Jan 31, 2026 | 153,000.00 |
| Oct 31, 2025 | 437,000.00 |
| Jul 31, 2025 | 704,000.00 |
| Apr 30, 2025 | 45,000.00 |
| Jan 31, 2025 | 299,000.00 |
| Oct 31, 2024 | 238,000.00 |
| Jul 31, 2024 | 2,000.00 |
| Apr 30, 2024 | 179,000.00 |
| Jan 31, 2024 | 506,000.00 |
| Oct 31, 2023 | 138,000.00 |
| Jul 31, 2023 | 157,000.00 |
| Apr 30, 2023 | 10,000.00 |
| Jan 31, 2023 | 13,000.00 |
API Access
enGene Therapeutics Capital Expenditures API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=capital-expenditures&ticker=ENGN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "capital-expenditures", "ticker": "ENGN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=capital-expenditures&ticker=ENGN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();